System1, Inc. Form 8-K Summary
Business Context and Reporting Period
System1, Inc. (SST), a Delaware corporation, filed this Current Report on Form 8-K on December 8, 2025. The filing addresses a regulatory notice received from the New York Stock Exchange (NYSE) regarding the Company's compliance with continued listing standards.
Key Financial Metrics and Listing Status
The filing identifies specific financial thresholds that triggered the NYSE notice:
- Market Capitalization: As of December 5, 2025, the 30 trading-day average market capitalization was less than $50 million.
- Stockholders' Equity: As of September 30, 2025, the last reported stockholders' equity was less than $50 million.
- Compliance Status: The Company is currently not in compliance with Section 802.01B of the NYSE Listed Company Manual.
The filing does not provide specific values for revenue, profit, cash flow, margins, or debt levels.
Material Changes and Regulatory Action
The primary material event is the receipt of a delisting notice due to failure to meet minimum market capitalization and stockholders' equity requirements. The Company has been granted an 18-month period to cure these deficiencies, contingent upon the NYSE's approval of a business plan demonstrating the ability to regain compliance.
Outlook, Management Commentary, and Risks
Management intends to notify the NYSE by December 22, 2025, of its plan to submit a business plan by January 22, 2026. The Company stated it will consider all available alternatives to cure the listing compliance deficiencies. The primary risk is the potential delisting from the NYSE if the Company fails to regain compliance within the 18-month cure period or fails to secure approval for its business plan.
Key Facts for Investor Verification
- Verify the exact 30-day average market capitalization and stockholders' equity figures in the most recent quarterly report (Q3 2025).
- Monitor the submission of the Company's business plan to the NYSE by January 22, 2026.
- Track the NYSE's formal approval or rejection of the proposed cure plan.
- Review the press release dated December 12, 2025 (Exhibit 99.1) for additional details on the Company's strategy.